[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556143":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":44,"locations":50,"responsibleParty":269,"collaborators":11,"id":271,"slug":272,"hasResults":273,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":11,"eligibilityCriteria":277,"healthyVolunteers":273,"sex":278,"minAge":279,"maxAge":11,"enrollmentInfo":280,"targetDuration":11,"studyType":283,"phases":284,"briefSummary":286,"conditions":287,"keywords":11,"overallStatus":101,"whyStopped":11,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":298},{"fullName":5,"class":6},"Beijing InnoCare Pharma Tech Co., Ltd.","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Tafasitamab and lenalidomide in combination with gemcitabine and oxaliplatin","EXPERIMENTAL",null,[13,14,15,16],"Drug: Tafasitamab","Drug: Lenalidomide","Drug: Gemcitabine","Drug: Oxaliplatin",{"label":18,"type":19,"description":11,"interventionNames":20},"Rituximab in combination with gemcitabine and oxaliplatin","ACTIVE_COMPARATOR",[15,16,21],"Drug: Rituximab",[23,28,32,36,40],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","Tafasitamab","Tafasitmab was infused intravenously",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"Lenalidomide","Lenalidomide orally",[9],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"Gemcitabine","Gemcitabine was infused intravenously",[18,9],{"type":24,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"Oxaliplatin","Oxaliplatin was infused intravenously",[18,9],{"type":24,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"Rituximab","Rituximab was infused intravenously.",[18],[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Weili Zhao","CONTACT","+86 021-64370045","zwl_trial@163.com",[51,66,77,88,99,111,122,133,141,152,160,171,182,193,203,214,225,236,247,258],{"facility":52,"status":53,"city":54,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Beijing Hospital","NOT_YET_RECRUITING","Beijing","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64],{"name":65,"role":47,"phone":11,"phoneExt":11,"email":11},"Hui Liu",{"facility":67,"status":53,"city":68,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"The First Hospital Of Jilin University","Changchun",{"type":58,"coordinates":70},[71,72],125.32278,43.88,{"lat":72,"lon":71},[75],{"name":76,"role":47,"phone":11,"phoneExt":11,"email":11},"Ou Bai",{"facility":78,"status":53,"city":79,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Hunan Cancer Hospital","Changsha",{"type":58,"coordinates":81},[82,83],112.97087,28.19874,{"lat":83,"lon":82},[86],{"name":87,"role":47,"phone":11,"phoneExt":11,"email":11},"Yajun Li",{"facility":89,"status":53,"city":90,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Chenzhou No.1 People's Hospital","Chaozhou",{"type":58,"coordinates":92},[93,94],116.62262,23.65396,{"lat":94,"lon":93},[97],{"name":98,"role":47,"phone":11,"phoneExt":11,"email":11},"Xinquan Liang",{"facility":100,"status":101,"city":102,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Sichuan Province People's Hospital","RECRUITING","Chengdu",{"type":58,"coordinates":104},[105,106],104.06667,30.66667,{"lat":106,"lon":105},[109],{"name":110,"role":47,"phone":11,"phoneExt":11,"email":11},"Rong Xiao",{"facility":112,"status":53,"city":113,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"The First Affiliated Hospital of Chongqing Medical University","Chongqing",{"type":58,"coordinates":115},[116,117],106.55771,29.56026,{"lat":117,"lon":116},[120],{"name":121,"role":47,"phone":11,"phoneExt":11,"email":11},"Hongbin Zhang",{"facility":123,"status":53,"city":124,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Guangdong General Hospital","Guangzhou",{"type":58,"coordinates":126},[127,128],113.25,23.11667,{"lat":128,"lon":127},[131],{"name":132,"role":47,"phone":11,"phoneExt":11,"email":11},"Wenyu Li",{"facility":134,"status":101,"city":124,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":135,"geoPoint":137,"contacts":138},"Sun Yat-sen University Cancer Center",{"type":58,"coordinates":136},[127,128],{"lat":128,"lon":127},[139],{"name":140,"role":47,"phone":11,"phoneExt":11,"email":11},"Qingqing Cai",{"facility":142,"status":53,"city":143,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Hangzhou First People's Hospital","Hangzhou",{"type":58,"coordinates":145},[146,147],120.16142,30.29365,{"lat":147,"lon":146},[150],{"name":151,"role":47,"phone":11,"phoneExt":11,"email":11},"Xiangmin Tong",{"facility":153,"status":53,"city":143,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":154,"geoPoint":156,"contacts":157},"The First Affiliated Hospital, Zhejiang University School of Medicine",{"type":58,"coordinates":155},[146,147],{"lat":147,"lon":146},[158],{"name":159,"role":47,"phone":11,"phoneExt":11,"email":11},"Wenjuan Yu",{"facility":161,"status":53,"city":162,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Shandong Cancer Hospital and Institute","Jinan",{"type":58,"coordinates":164},[165,166],116.99722,36.66833,{"lat":166,"lon":165},[169],{"name":170,"role":47,"phone":11,"phoneExt":11,"email":11},"Zengjun Li",{"facility":172,"status":53,"city":173,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Jiangxi Cancer Hospital","Nanchang",{"type":58,"coordinates":175},[176,177],115.85306,28.68396,{"lat":177,"lon":176},[180],{"name":181,"role":47,"phone":11,"phoneExt":11,"email":11},"Yan Huang",{"facility":183,"status":53,"city":184,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"The First Affiliated Hospital of Nanchang University","Nanjing",{"type":58,"coordinates":186},[187,188],118.77778,32.06167,{"lat":188,"lon":187},[191],{"name":192,"role":47,"phone":11,"phoneExt":11,"email":11},"Fei Li",{"facility":194,"status":53,"city":195,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Ruijin Hospital Shanghai Jiaotong University School of Medicine","Shanghai",{"type":58,"coordinates":197},[198,199],121.45806,31.22222,{"lat":199,"lon":198},[202],{"name":46,"role":47,"phone":11,"phoneExt":11,"email":11},{"facility":204,"status":101,"city":205,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"The Second Affiliated Hospital of Soochow University","Suzhou",{"type":58,"coordinates":207},[208,209],120.59538,31.30408,{"lat":209,"lon":208},[212],{"name":213,"role":47,"phone":11,"phoneExt":11,"email":11},"Bingzong Li",{"facility":215,"status":53,"city":216,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"Tianjin First Central Hospital","Tianjin",{"type":58,"coordinates":218},[219,220],117.17667,39.14222,{"lat":220,"lon":219},[223],{"name":224,"role":47,"phone":11,"phoneExt":11,"email":11},"Qi Deng",{"facility":226,"status":53,"city":227,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"Xinjiang Medical University Affiliated Cancer Hospital","Ürümqi",{"type":58,"coordinates":229},[230,231],87.60046,43.80096,{"lat":231,"lon":230},[234],{"name":235,"role":47,"phone":11,"phoneExt":11,"email":11},"Shujuan Wen",{"facility":237,"status":53,"city":238,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"The First Affiliated Hospital Wenzhou Medical University","Wenzhou",{"type":58,"coordinates":240},[241,242],120.66682,27.99942,{"lat":242,"lon":241},[245],{"name":246,"role":47,"phone":11,"phoneExt":11,"email":11},"Songfu Jiang",{"facility":248,"status":53,"city":249,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":250,"geoPoint":254,"contacts":255},"Union Hospital Tongji Medical College","Wuhan",{"type":58,"coordinates":251},[252,253],114.26667,30.58333,{"lat":253,"lon":252},[256],{"name":257,"role":47,"phone":11,"phoneExt":11,"email":11},"Liling Zhang",{"facility":259,"status":53,"city":260,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"Henan Cancer Hospital","Zhengzhou",{"type":58,"coordinates":262},[263,264],113.64861,34.75778,{"lat":264,"lon":263},[267],{"name":268,"role":47,"phone":11,"phoneExt":11,"email":11},"Keshu Zhou",{"type":270,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100556143","phase-3-evaluate-the-safety-and-efficacy-of-tafasitamab-and-lenalidomide-in-combination-with-gemcitabine-and-oxaliplatin-versus-rituximab-in-combination-with-gemcitabine-and-oxaliplatin-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-100556143",false,"NCT06521255","Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n1. 18 Years and older.\n2. One of the histologies of DLBCL confirmed by participated sites below with，not otherwise specified;T-cell\u002Fhistiocyte-rich large B-cell lymphoma;Epstein-Barr virus (EBV) positive DLBCL (EBV-positive DLBCL); Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse; Disease transformed from an earlier diagnosis of low-grade lymphoma into DLBCL with DLBCL treatment failure.\n3. Availability of tumor tissue biopsied post last line of therapy and prior to current study treatment for the patients enrolled in safety and tolerability stage.\n4. Relapsed\u002Frefractory (R\u002FR) DLBCL, at least one (≥1) but no more than three (≤3) line of prior systemic therapies.\n5. Patients who have not received high dose therapy\u002Fstem cell transplantation (HDT\u002FSCT) must be ineligible for HDT\u002FSCT.\n6. At least one measurable site of disease per CT or magnetic resonance imaging (the longest axis of the lymph node lesion is \\> 1.5 cm, and the longest diameter of the extra-nodal lesion is \\> 1.0 cm).\n7. ECOG PS score of 0 to 2.\n8. Subject must have adequate organ functions, and the laboratory values comply with the protocol requirements.\n9. Life expectancy of ≥ 3 months.\n10. Informed consent before screening and can understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. Existing or prior history of other malignant tumor within 3 years, except for those who have received curative treatment.\n2. Current or history of central nervous system (CNS) lymphoma.\n3. Known high-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements.\n4. Primary mediastinal B-cell lymphoma.\n5. History of allogeneic stem-cell transplantation.\n6. Prior exposure to anti-CD19 treatment, and (or) failed with gemcitabine plus platinum-based agent combination therapy.\n7. Current toxicity of ≥ Grade 2 from prior anti-cancer therapy (except for alopecia, neutrophil, hemoglobin and platelets).\n8. Clinically significant cardiovascular disease or nervous system disease.\n9. History of deep venous thrombosis\u002Fembolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing\u002Fable to take venous thromboembolic event prophylaxis during the entire treatment period.\n10. Uncontrolled systemic infection requiring parenteral intravenous anti-infective therapy.\n11. Known human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B or C infection.","ALL","18 Years",{"count":281,"type":282},244,"ESTIMATED","INTERVENTIONAL",[285],"PHASE3","This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed\u002FRefractory Diffuse Large B-Cell Lymphom",[288],"DLBCL","2024-07-24",{"date":291,"type":292},"2024-07-25","ACTUAL",{"date":294,"type":292},"2024-05-07",{"date":296,"type":282},"2029-12",{"name":5,"class":6},20]